Transcend Capital Advisors’s RxSight RXST Stock Holding History

Transcend Capital Advisors’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,503	Closed	-$417K	–	704
2025 Q1	$417K	Buy	16,503 +3	+0%	+$89	0.03%	399
2024 Q4	$567K	Hold	16,500	–	–	0.04%	322
2024 Q3	$816K	Sell	16,500 -335	-2%	-$17.2K	0.05%	300
2024 Q2	$1.01M	Sell	16,835 -285	-2%	-$16.3K	0.07%	249
2024 Q1	$883K	Buy	17,120 +620	+4%	+$30.4K	0.07%	249
2023 Q4	$665K	Hold	16,500	–	–	0.06%	271
2023 Q3	$460K	Hold	16,500	–	–	0.04%	304
2023 Q2	$475K	Buy	+16,500	New	+$367K	0.05%	307

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Transcend Capital Advisors's RXST Position: Q2 2025 in Review

Transcend Capital Advisors sold out of RxSight (RXST) in Q2 2025, closing a stake of 16,503 shares — an estimated $417K sold.

Transcend Capital Advisors first reported a position in RXST in Q2 2023 and held it in 8 quarters. The position peaked at $1.01M in Q2 2024. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

Transcend Capital Advisors reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
Transcend Capital Advisors sold 16,503 RxSight shares in Q2 2025, an estimated $417K.
Transcend Capital Advisors first reported a position in RxSight in Q2 2023 and held it in 8 quarters.
Transcend Capital Advisors's RxSight position peaked at $1.01M in Q2 2024.
174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on Transcend Capital Advisors's 13F filing for Q2 2025, filed 1 Aug 2025.